Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application
G protein‐coupled receptors (GPCRs) can be used to shuttle peptide‐drug conjugates into cells. But, for efficient therapy, a high concentration of cargo needs to be delivered. To explore this, we studied the pharmacologically interesting neuropeptide Y1 receptor (Y1R) in one recombinant and three on...
Gespeichert in:
Veröffentlicht in: | ChemMedChem 2021-01, Vol.16 (1), p.164-178 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 178 |
---|---|
container_issue | 1 |
container_start_page | 164 |
container_title | ChemMedChem |
container_volume | 16 |
creator | Ziffert, Isabelle Kaiser, Anette Hoppenz, Paul Mörl, Karin Beck‐Sickinger, Annette G. |
description | G protein‐coupled receptors (GPCRs) can be used to shuttle peptide‐drug conjugates into cells. But, for efficient therapy, a high concentration of cargo needs to be delivered. To explore this, we studied the pharmacologically interesting neuropeptide Y1 receptor (Y1R) in one recombinant and three oncogenic cell systems that endogenously express the receptor. We demonstrate that recycled receptors behave identically to newly synthesized receptors with respect to ligand binding and internalization pathways. Depending on the cell system, biosynthesis, recycling efficiency, and peptide uptake differ partially, but shuttling was efficient in all systems. However, by comparing continuous application of the ligand for four hours to four cycles of internalization and recycling in between, a significantly higher amount of peptide uptake was achieved in the pulsed application (150–250 % to 300–400 %). Accordingly, in this well‐suited drug shuttle system pulsed application is superior under all investigated conditions and should be considered for innovative, targeted drug delivery in general.
The sensitive equilibrium of receptor activation and desensitization is complex, and detailed knowledge is required for applications that use GPCRs as a shuttle system for intracellular drug delivery. As Y1R is overexpressed in various cancer subtypes, its shuttling capacity was quantitatively examined in diverse cell systems and by different methods to exploit its natural ligand‐induced endocytosis for targeted therapy. |
doi_str_mv | 10.1002/cmdc.202000490 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7818256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426536501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4680-27e5e86d8113828c646a79e3b271e06378bd6aff82c9427883ec57fc9964721c3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxiMEoqVw5YgicUFCu9hOYjsXpCqFslIRKwpnK-tMUq8SO7WdVnvrI_QZeRJm2WX5c4GTR57f92lmviR5TsmcEsLe6KHRc0YYISQvyYPkmEpOZoJK8fBQi_IoeRLCGpFcUvk4OcqYICQr6XFye3k1xdgb26WuTZcwRtPAt7v7Mz91aeXseurqCCFdbdLzdOldBGOxXblp7KFJP4NGifMhXYT00nTWtEbXNvabdDGM3t0gg9Ll1AesTsexx3Y0zj5NHrU1fj7bvyfJ1_fvvlQfZhefzhfV6cVM51ySGRNQgOSNpDSTTGqe81qUkK2YoEB4JuSq4XXbSqbLnAkpM9CFaHVZ8lwwqrOT5O3Od5xWAzQabPR1r0ZvhtpvlKuN-rNjzZXq3I0SeClWcDR4tTfw7nqCENVggoa-ry24KSiWM15kvCAU0Zd_oWs3eYvrISV4llPCttR8R2nvQvDQHoahRG0zVdtM1SFTFLz4fYUD_jNEBOQOuIWVa4M2YDUcMHQpcEIhkCaEVib-CAATtBGlr_9finS5p00Pm3_MraqPZ9WvLb4DQprRTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476341021</pqid></control><display><type>article</type><title>Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Ziffert, Isabelle ; Kaiser, Anette ; Hoppenz, Paul ; Mörl, Karin ; Beck‐Sickinger, Annette G.</creator><creatorcontrib>Ziffert, Isabelle ; Kaiser, Anette ; Hoppenz, Paul ; Mörl, Karin ; Beck‐Sickinger, Annette G.</creatorcontrib><description>G protein‐coupled receptors (GPCRs) can be used to shuttle peptide‐drug conjugates into cells. But, for efficient therapy, a high concentration of cargo needs to be delivered. To explore this, we studied the pharmacologically interesting neuropeptide Y1 receptor (Y1R) in one recombinant and three oncogenic cell systems that endogenously express the receptor. We demonstrate that recycled receptors behave identically to newly synthesized receptors with respect to ligand binding and internalization pathways. Depending on the cell system, biosynthesis, recycling efficiency, and peptide uptake differ partially, but shuttling was efficient in all systems. However, by comparing continuous application of the ligand for four hours to four cycles of internalization and recycling in between, a significantly higher amount of peptide uptake was achieved in the pulsed application (150–250 % to 300–400 %). Accordingly, in this well‐suited drug shuttle system pulsed application is superior under all investigated conditions and should be considered for innovative, targeted drug delivery in general.
The sensitive equilibrium of receptor activation and desensitization is complex, and detailed knowledge is required for applications that use GPCRs as a shuttle system for intracellular drug delivery. As Y1R is overexpressed in various cancer subtypes, its shuttling capacity was quantitatively examined in diverse cell systems and by different methods to exploit its natural ligand‐induced endocytosis for targeted therapy.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.202000490</identifier><identifier>PMID: 32700391</identifier><language>eng</language><publisher>WEINHEIM: Wiley</publisher><subject>Biosynthesis ; cancer ; cell lines ; Chemistry, Medicinal ; Conjugates ; Drug delivery ; Internalization ; Life Sciences & Biomedicine ; Ligands ; neuropeptide Y ; Peptides ; Pharmacology & Pharmacy ; Protein turnover ; Proteins ; Receptors ; Science & Technology ; shuttling</subject><ispartof>ChemMedChem, 2021-01, Vol.16 (1), p.164-178</ispartof><rights>2020 The Authors. Published by Wiley-VCH GmbH</rights><rights>2020 The Authors. Published by Wiley-VCH GmbH.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000565377700001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4680-27e5e86d8113828c646a79e3b271e06378bd6aff82c9427883ec57fc9964721c3</citedby><cites>FETCH-LOGICAL-c4680-27e5e86d8113828c646a79e3b271e06378bd6aff82c9427883ec57fc9964721c3</cites><orcidid>0000-0003-4560-8020 ; 0000-0003-3437-0619 ; 0000-0002-5477-201X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.202000490$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.202000490$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,39263,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32700391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ziffert, Isabelle</creatorcontrib><creatorcontrib>Kaiser, Anette</creatorcontrib><creatorcontrib>Hoppenz, Paul</creatorcontrib><creatorcontrib>Mörl, Karin</creatorcontrib><creatorcontrib>Beck‐Sickinger, Annette G.</creatorcontrib><title>Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application</title><title>ChemMedChem</title><addtitle>CHEMMEDCHEM</addtitle><addtitle>ChemMedChem</addtitle><description>G protein‐coupled receptors (GPCRs) can be used to shuttle peptide‐drug conjugates into cells. But, for efficient therapy, a high concentration of cargo needs to be delivered. To explore this, we studied the pharmacologically interesting neuropeptide Y1 receptor (Y1R) in one recombinant and three oncogenic cell systems that endogenously express the receptor. We demonstrate that recycled receptors behave identically to newly synthesized receptors with respect to ligand binding and internalization pathways. Depending on the cell system, biosynthesis, recycling efficiency, and peptide uptake differ partially, but shuttling was efficient in all systems. However, by comparing continuous application of the ligand for four hours to four cycles of internalization and recycling in between, a significantly higher amount of peptide uptake was achieved in the pulsed application (150–250 % to 300–400 %). Accordingly, in this well‐suited drug shuttle system pulsed application is superior under all investigated conditions and should be considered for innovative, targeted drug delivery in general.
The sensitive equilibrium of receptor activation and desensitization is complex, and detailed knowledge is required for applications that use GPCRs as a shuttle system for intracellular drug delivery. As Y1R is overexpressed in various cancer subtypes, its shuttling capacity was quantitatively examined in diverse cell systems and by different methods to exploit its natural ligand‐induced endocytosis for targeted therapy.</description><subject>Biosynthesis</subject><subject>cancer</subject><subject>cell lines</subject><subject>Chemistry, Medicinal</subject><subject>Conjugates</subject><subject>Drug delivery</subject><subject>Internalization</subject><subject>Life Sciences & Biomedicine</subject><subject>Ligands</subject><subject>neuropeptide Y</subject><subject>Peptides</subject><subject>Pharmacology & Pharmacy</subject><subject>Protein turnover</subject><subject>Proteins</subject><subject>Receptors</subject><subject>Science & Technology</subject><subject>shuttling</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>HGBXW</sourceid><recordid>eNqNkc9u1DAQxiMEoqVw5YgicUFCu9hOYjsXpCqFslIRKwpnK-tMUq8SO7WdVnvrI_QZeRJm2WX5c4GTR57f92lmviR5TsmcEsLe6KHRc0YYISQvyYPkmEpOZoJK8fBQi_IoeRLCGpFcUvk4OcqYICQr6XFye3k1xdgb26WuTZcwRtPAt7v7Mz91aeXseurqCCFdbdLzdOldBGOxXblp7KFJP4NGifMhXYT00nTWtEbXNvabdDGM3t0gg9Ll1AesTsexx3Y0zj5NHrU1fj7bvyfJ1_fvvlQfZhefzhfV6cVM51ySGRNQgOSNpDSTTGqe81qUkK2YoEB4JuSq4XXbSqbLnAkpM9CFaHVZ8lwwqrOT5O3Od5xWAzQabPR1r0ZvhtpvlKuN-rNjzZXq3I0SeClWcDR4tTfw7nqCENVggoa-ry24KSiWM15kvCAU0Zd_oWs3eYvrISV4llPCttR8R2nvQvDQHoahRG0zVdtM1SFTFLz4fYUD_jNEBOQOuIWVa4M2YDUcMHQpcEIhkCaEVib-CAATtBGlr_9finS5p00Pm3_MraqPZ9WvLb4DQprRTQ</recordid><startdate>20210108</startdate><enddate>20210108</enddate><creator>Ziffert, Isabelle</creator><creator>Kaiser, Anette</creator><creator>Hoppenz, Paul</creator><creator>Mörl, Karin</creator><creator>Beck‐Sickinger, Annette G.</creator><general>Wiley</general><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4560-8020</orcidid><orcidid>https://orcid.org/0000-0003-3437-0619</orcidid><orcidid>https://orcid.org/0000-0002-5477-201X</orcidid></search><sort><creationdate>20210108</creationdate><title>Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application</title><author>Ziffert, Isabelle ; Kaiser, Anette ; Hoppenz, Paul ; Mörl, Karin ; Beck‐Sickinger, Annette G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4680-27e5e86d8113828c646a79e3b271e06378bd6aff82c9427883ec57fc9964721c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biosynthesis</topic><topic>cancer</topic><topic>cell lines</topic><topic>Chemistry, Medicinal</topic><topic>Conjugates</topic><topic>Drug delivery</topic><topic>Internalization</topic><topic>Life Sciences & Biomedicine</topic><topic>Ligands</topic><topic>neuropeptide Y</topic><topic>Peptides</topic><topic>Pharmacology & Pharmacy</topic><topic>Protein turnover</topic><topic>Proteins</topic><topic>Receptors</topic><topic>Science & Technology</topic><topic>shuttling</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ziffert, Isabelle</creatorcontrib><creatorcontrib>Kaiser, Anette</creatorcontrib><creatorcontrib>Hoppenz, Paul</creatorcontrib><creatorcontrib>Mörl, Karin</creatorcontrib><creatorcontrib>Beck‐Sickinger, Annette G.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ziffert, Isabelle</au><au>Kaiser, Anette</au><au>Hoppenz, Paul</au><au>Mörl, Karin</au><au>Beck‐Sickinger, Annette G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application</atitle><jtitle>ChemMedChem</jtitle><stitle>CHEMMEDCHEM</stitle><addtitle>ChemMedChem</addtitle><date>2021-01-08</date><risdate>2021</risdate><volume>16</volume><issue>1</issue><spage>164</spage><epage>178</epage><pages>164-178</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>G protein‐coupled receptors (GPCRs) can be used to shuttle peptide‐drug conjugates into cells. But, for efficient therapy, a high concentration of cargo needs to be delivered. To explore this, we studied the pharmacologically interesting neuropeptide Y1 receptor (Y1R) in one recombinant and three oncogenic cell systems that endogenously express the receptor. We demonstrate that recycled receptors behave identically to newly synthesized receptors with respect to ligand binding and internalization pathways. Depending on the cell system, biosynthesis, recycling efficiency, and peptide uptake differ partially, but shuttling was efficient in all systems. However, by comparing continuous application of the ligand for four hours to four cycles of internalization and recycling in between, a significantly higher amount of peptide uptake was achieved in the pulsed application (150–250 % to 300–400 %). Accordingly, in this well‐suited drug shuttle system pulsed application is superior under all investigated conditions and should be considered for innovative, targeted drug delivery in general.
The sensitive equilibrium of receptor activation and desensitization is complex, and detailed knowledge is required for applications that use GPCRs as a shuttle system for intracellular drug delivery. As Y1R is overexpressed in various cancer subtypes, its shuttling capacity was quantitatively examined in diverse cell systems and by different methods to exploit its natural ligand‐induced endocytosis for targeted therapy.</abstract><cop>WEINHEIM</cop><pub>Wiley</pub><pmid>32700391</pmid><doi>10.1002/cmdc.202000490</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-4560-8020</orcidid><orcidid>https://orcid.org/0000-0003-3437-0619</orcidid><orcidid>https://orcid.org/0000-0002-5477-201X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1860-7179 |
ispartof | ChemMedChem, 2021-01, Vol.16 (1), p.164-178 |
issn | 1860-7179 1860-7187 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7818256 |
source | Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
subjects | Biosynthesis cancer cell lines Chemistry, Medicinal Conjugates Drug delivery Internalization Life Sciences & Biomedicine Ligands neuropeptide Y Peptides Pharmacology & Pharmacy Protein turnover Proteins Receptors Science & Technology shuttling |
title | Shuttling of Peptide‐Drug Conjugates by G Protein‐Coupled Receptors Is Significantly Improved by Pulsed Application |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T10%3A28%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Shuttling%20of%20Peptide%E2%80%90Drug%20Conjugates%20by%20G%20Protein%E2%80%90Coupled%20Receptors%20Is%20Significantly%20Improved%20by%20Pulsed%20Application&rft.jtitle=ChemMedChem&rft.au=Ziffert,%20Isabelle&rft.date=2021-01-08&rft.volume=16&rft.issue=1&rft.spage=164&rft.epage=178&rft.pages=164-178&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.202000490&rft_dat=%3Cproquest_pubme%3E2426536501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476341021&rft_id=info:pmid/32700391&rfr_iscdi=true |